ABBV vs. TSLA: AbbVie vs. Tesla Stock Comparison

November 11, 2026

How do AbbVie (ABBV) and Tesla (TSLA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AbbVie (ABBV) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Tesla (TSLA) belongs to Consumer Discretionary (Automobiles & Components) — their GICS classifications point to very different parts of the market.

Company profile comparison for AbbVie (ABBV) and Tesla (TSLA)
Profile Item	ABBV	TSLA
Name	AbbVie Inc.	Tesla, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Consumer Discretionary
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Automobiles & Components
GICS Industry	Biotechnology	Automobiles
GICS Sub-Industry	Biotechnology	Automobile Manufacturers
Market Capitalization	514.92 billion USD	1,415.96 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	January 2, 2013	June 29, 2010
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ABBV

TSLA

GSPC

AbbVie (ABBV) vs. Tesla (TSLA), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for AbbVie (ABBV) and Tesla (TSLA). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for AbbVie (ABBV) and Tesla (TSLA). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AbbVie (ABBV) and Tesla (TSLA)
Metric	ABBV	TSLA
Total Return (1Y)	37.33%	-12.23%
Total Return (3Y, Annualized)	32.74%	21.54%
Total Return (5Y, Annualized)	24.73%	2.02%

Risk Profile

Drawdown History

ABBV

TSLA

GSPC

AbbVie (ABBV) vs. Tesla (TSLA), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for AbbVie (ABBV) and Tesla (TSLA). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Tesla (TSLA) has an aggressive beta of 1.75, indicating higher sensitivity to broad-market moves, while AbbVie (ABBV) is defensive at 0.21 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk profile metrics for AbbVie (ABBV) and Tesla (TSLA)
Metric	ABBV	TSLA
Volatility (1Y, Annualized)	25.65%	45.89%
Beta (5Y)	0.21	1.75
Max Drawdown (5Y)	-21.92%	-72.97%
Avg. Volume (3M)	4.76M	37.45M

Risk-Adjusted Performance

Risk-Return Positioning

ABBV and TSLA are plotted by 1-year volatility (risk) and 1-year return. Each dashed Capital Allocation Line uses that stock's own industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AbbVie (ABBV) and Tesla (TSLA)
Metric	ABBV	TSLA
Sharpe Ratio (1Y)	1.29	-0.36
Sortino Ratio (1Y)	2.02	-0.49

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Tesla (TSLA) earns 3.84% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
ABBV: --

TSLA

Automobiles & Components industry group

3.84%

Max: 43.84%
Q3: 11.73%
TSLA: 3.84%
Median: 3.48%
Q1: -19.67%
Min: -54.88%

AbbVie (ABBV) vs. Tesla (TSLA): ABBV does not report ROE, so it has no value marker; TSLA is benchmarked against the Automobiles & Components industry group.

Net Margin (TTM)

AbbVie (ABBV) at 15.67% retains a top-quartile share of revenue as profit, ahead of Tesla (TSLA) at 3.11%, which keeps about the industry-typical share.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.67%

Max: 18.05%
ABBV: 15.67%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TSLA

Automobiles & Components industry group

3.11%

Max: 15.15%
Q3: 4.78%
TSLA: 3.11%
Median: 1.56%
Q1: -4.16%
Min: -9.55%

AbbVie (ABBV) vs. Tesla (TSLA): A comparison of their net margin against their respective Pharmaceuticals, Biotechnology & Life Sciences and Automobiles & Components industry group benchmarks.

Operating Margin (TTM)

AbbVie (ABBV) at 39.59% operates in the top operating margin quartile, ahead of Tesla (TSLA) at 5.36%, which runs around its industry’s norm.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.59%

Max: 83.12%
ABBV: 39.59%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TSLA

Automobiles & Components industry group

5.36%

Max: 18.35%
Q3: 8.67%
TSLA: 5.36%
Median: 4.42%
Q1: 0.00%
Min: -8.50%

AbbVie (ABBV) vs. Tesla (TSLA): A comparison of their operating margin against their respective Pharmaceuticals, Biotechnology & Life Sciences and Automobiles & Components industry group benchmarks.

Profitability Metrics

Profitability metrics for AbbVie (ABBV) and Tesla (TSLA)
Metric	ABBV	TSLA
ROE (TTM)	--	3.84%
ROA (TTM)	10.74%	1.35%
Net Margin (TTM)	15.67%	3.11%
Operating Margin (TTM)	39.59%	5.36%
Gross Margin (TTM)	73.72%	19.29%

Growth

Revenue Growth

AbbVie (ABBV) at 8.57% is around its peer norm for revenue growth, while Tesla (TSLA) at -2.93% drops into the bottom quartile, signaling weaker demand or pricing momentum.

AbbVie (ABBV) vs. Tesla (TSLA): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both AbbVie (ABBV) at -0.84% and Tesla (TSLA) at -47.06% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

AbbVie (ABBV) vs. Tesla (TSLA): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AbbVie (ABBV) and Tesla (TSLA)
Metric	ABBV	TSLA
Revenue Growth (YoY)	8.57%	-2.93%
Revenue Growth (3Y CAGR)	1.75%	5.19%
EPS Growth (YoY)	-0.84%	-47.06%
EPS Growth (3Y CAGR)	-29.03%	-33.18%

Financial Strength

Current Ratio (MRQ)

Tesla (TSLA) at 1.74 keeps current ratio within its industry’s typical mid-range, while AbbVie (ABBV) at 0.87 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ABBV.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ABBV: 0.87
Min: 0.10

TSLA

Automobiles & Components industry group

1.74

Max: 3.65
Q3: 2.31
TSLA: 1.74
Median: 1.65
Q1: 1.13
Min: 0.32

AbbVie (ABBV) vs. Tesla (TSLA): A comparison of their current ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Automobiles & Components industry group benchmarks.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Tesla (TSLA) carries debt-to-equity ratio of 0.18 against its industry range, while AbbVie (ABBV) reports no figure this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
ABBV: --

TSLA

Automobiles & Components industry group

0.18

Max: 2.03
Q3: 1.13
Median: 0.76
Q1: 0.33
TSLA: 0.18
Min: 0.01

AbbVie (ABBV) vs. Tesla (TSLA): ABBV does not report debt-to-equity ratio, so it has no value marker; TSLA is benchmarked against the Automobiles & Components industry group.

Financial Strength Metrics

Financial strength metrics for AbbVie (ABBV) and Tesla (TSLA)
Metric	ABBV	TSLA
Current Ratio (MRQ)	0.87	1.74
Debt / Equity (MRQ)	--	0.18
Net Debt / EBITDA	2.21	-2.95

Dividends

Dividend Yield (TTM)

Tesla (TSLA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40%

ABBV: 2.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TSLA

Automobiles & Components industry group

0.00%

Max: 4.79%
Q3: 2.24%
TSLA: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Tesla (TSLA): A comparison of their dividend yield against their respective Pharmaceuticals, Biotechnology & Life Sciences and Automobiles & Components industry group benchmarks.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; Tesla (TSLA) pays no dividend (payout 0.00%).

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.35%

ABBV: 117.35%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TSLA

Automobiles & Components industry group

0.00%

Max: 64.17%
Q3: 36.51%
TSLA: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Tesla (TSLA): A comparison of their payout ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Automobiles & Components industry group benchmarks.

Dividend Metrics

Dividend metrics for AbbVie (ABBV) and Tesla (TSLA)
Metric	ABBV	TSLA
Dividend Yield (TTM)	2.40%	0.00%
Dividend Payout Ratio (TTM)	117.35%	0.00%

Valuation

P/E Ratio (TTM)

Both look expensive on trailing earnings: AbbVie (ABBV) at 50.05 sits in the richer P/E ratio quartile, and Tesla (TSLA) at 393.65 is richer still, above its industry range.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

50.05

Max: 85.34
ABBV: 50.05
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

TSLA

Automobiles & Components industry group

393.65

TSLA: 393.65
Max: 40.42
Q3: 24.40
Median: 19.50
Q1: 11.03
Min: 6.05

AbbVie (ABBV) vs. Tesla (TSLA): A comparison of their P/E ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Automobiles & Components industry group benchmarks.

P/S Ratio (TTM)

AbbVie (ABBV) at 7.80 prices around its industry’s typical P/S ratio, while Tesla (TSLA) at 13.67 clears its benchmark range — TSLA looks notably rich on sales.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.80

Max: 58.18
Q3: 25.77
ABBV: 7.80
Median: 7.30
Q1: 3.01
Min: 0.01

TSLA

Automobiles & Components industry group

13.67

TSLA: 13.67
Max: 2.03
Q3: 0.99
Median: 0.51
Q1: 0.23
Min: 0.00

AbbVie (ABBV) vs. Tesla (TSLA): A comparison of their P/S ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Automobiles & Components industry group benchmarks.

P/B Ratio (MRQ)

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Tesla (TSLA) reports 15.86, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-112.34

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
ABBV: -112.34

TSLA

Automobiles & Components industry group

15.86

TSLA: 15.86
Max: 4.18
Q3: 2.39
Median: 1.33
Q1: 0.72
Min: -1.23

AbbVie (ABBV) vs. Tesla (TSLA): A comparison of their P/B ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Automobiles & Components industry group benchmarks.

Valuation Metrics

Valuation metrics for AbbVie (ABBV) and Tesla (TSLA)
Metric	ABBV	TSLA
P/E Ratio (TTM)	50.05	393.65
P/S Ratio (TTM)	7.80	13.67
P/B Ratio (MRQ)	-112.34	15.86
Free Cash Flow Yield (TTM)	3.44%	0.35%